Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

Psoriasis is a common inflammatory skin disease with multiple comorbidities, including
psoriatic arthritis and coronary artery disease, that can severely impact an individual's …

Background Risankizumab has demonstrated efficacy and safety in patients with moderate‐
to‐severe plaque psoriasis in randomized clinical trials. Objectives To evaluate safety data …

Background Psoriasis is a chronic inflammatory skin disease requiring prolonged treatment.
New biologic therapies require long‐term evaluation to assess the durability of their efficacy …

The approved biologics targeting interleukin (IL)-23 p19 for the treatment of moderate-to-
severe plaque psoriasis, including guselkumab, tildrakizumab, and risankizumab, have …

Objective Innate lymphoid cells (ILCs) are a recently discovered group of cells that are
essential to epithelial homeostasis and are implicated in psoriasis pathogenesis, yet they …

Risankizumab has been recently approved for moderate‐to‐severe plaque psoriasis;
however, real‐life studies are scarce. Analysis of possible predictor factors of treatment …

Background and objectives A new, updated AEDV Psoriasis Group (GPs) consensus
document on the treatment of moderate to severe psoriasis was needed owing to the …

Psoriasis is an immune-mediated inflammatory skin disease associated with numerous
inflammatory comorbidities, including increased cardiovascular risk. The interleukin (IL) …

As the first biologics for psoriasis in Japan, infliximab and adalimumab, anti‐tumor necrosis
factor‐α antibodies, became available in the field of dermatology in 2010, followed by …